NewsRoom Articles - Page 2 of 250

MondaySep 21, 2026 10:30 am

Earth Science Tech Inc.’s (ETST) Uplist to OTCQB Venture Market Continues Series of Milestones in Fiscal 2027

Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that provides investors with a trusted trading environment The uplisting is one of several milestones the company has reported during the current financial year 2027, which began on April 1, 2026 The company reported its Q1 2027 financial results, marking a 3% growth in revenue with a 57% increase in net income The company also acquired Meduvo LLC and Zoolzy and held its annual meeting of shareholders Earth Science Tech (OTCQB: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, successfully uplisted to…

MondaySep 21, 2026 9:45 am

VERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered the NASDAQ market in June 2026 following its completed business combination with Voyager Acquisition Corp., giving VERAXA access to the U.S. public markets as it advances its development programs. BiTAC is designed as an “AND-gated” therapeutic approach in which two complementary components must engage the same cancer cell before the intended cytotoxic mechanism is activated. VERAXA has reported early preclinical evidence for both its BiTAC-TCE and BiTAC-ADC approaches, including an in-vitro proof of concept for BiTAC-ADC announced in…

FridaySep 18, 2026 10:00 am

Bacterial Strains Influence Meningitis, Pneumonia Risks from Air Pollution, New Study Finds

A new study has found that the risk of people developing sepsis, meningitis or pneumonia as a result of exposure to air pollution is influenced by the specific bacterial strains that an individual carries within their microbiome. The study, whose findings were published in the journal Nature Microbiology on September 14 this year, was conducted by a joint team from the South African National Institute of Communicable Diseases, the Supercomputing Center in Barcelona, Spain, together with other collaborators. The researchers focused on Streptococcus pneumoniae, a bacterium that lives within the respiratory microbiome. It typically lives inside the throat and nose,…

ThursdaySep 17, 2026 10:00 am

Accelerated Biological Aging Could Explain Why Younger Adults are Getting Cancer

Scientists have been struggling to understand why more people who are less than 55 years of age are being diagnosed with cancer. These cases are described as early-onset cancer because cancers typically tend to develop in people above 55, but this is changing and researchers want to know why. It was “understandable” when people were diagnosed with cancer at 55 years or beyond because as the body gets older, it accumulates damage at the cellular level to the extent that tumor development begins. Now that younger people are developing cancer, the scientific community is racing to find out why, even…

TuesdaySep 15, 2026 10:00 am

Systemic Challenges in US Health Care Push Cancer Patients to Fly to China

For decades, lots of American patients have been traveling to “fringe” countries like Turkey, Cuba and Thailand in search of affordable, quality healthcare due to the persistent challenges plaguing the American health care system. Now the latest destination of choice for cancer treatment is China, according to a report by the WSJ (Wall Street Journal). CAR-T therapy, a new type of cancer treatment that bioengineers immune cells of a cancer patient in order to make them more potent against cancer, was developed in the U.S. However, the high cost of this treatment, together with the lengthy process of engineering the…

TuesdaySep 15, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell. The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors. With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value. VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a…

MondaySep 14, 2026 9:00 am

Earth Science Tech Inc.’s (ETST) Shareholders Approve Key Proposals in Annual Meeting

Earth Science Tech held its first annual meeting of stockholders, virtually, on August 31, 2026+ The shareholders authorized the Board to pursue a reverse stock split, if deemed necessary, to help the company uplist to a national exchange like Nasdaq or NYSE During the meeting, stockholders authorized the Board’s Independent Special Committee to negotiate the retirement of the Series B Preferred Stock, which would eliminate the current dual-class voting structure The shareholders also ratified the appointment of Semple, Marchal & Cooper LLP, as an independent registered public accounting firm, re-elected seven director nominees, and authorized a new non-dilutive executive compensation…

FridaySep 11, 2026 10:00 am

Rising Rates of the Uninsured Could Affect Every American

As more Americans become underinsured or uninsured as a result of rising health insurance premiums and the several changes that were passed in the Big Beautiful Act, the impacts of the rising numbers of the uninsured are likely to be felt by every American. Several healthcare professionals have sounded the alarm on this brewing issue. The Congressional Budget Office estimates that by 2034, about 16 million Americans will be uninsured. One of the factors contributing to people becoming uninsured is the H.R. 1 requirement for people on Medicaid to reconfirm their address and work situation at six-month intervals in order to remain on Medicaid. Safety net hospitals already operate on tight margins because…

FridaySep 11, 2026 9:00 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss. Regentis Biomaterials’ GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment. Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe, while an FDA-authorized pivotal trial is advancing its development toward potential U.S. approval. A knee that once carried a runner through marathons or a hiker up a steep mountainside can be sidelined by a single defect in cartilage. More broadly,…

ThursdaySep 10, 2026 9:00 am

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (Profile) has received U.S. Food and Drug Administration (“FDA”) clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class candidate designed…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Earth Science Tech Inc.’s (ETST) Uplist to OTCQB Venture Market Continues Series of Milestones in Fiscal 2027

VERAXA Biotech AG (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

Bacterial Strains Influence Meningitis, Pneumonia Risks from Air Pollution, New Study Finds

Accelerated Biological Aging Could Explain Why Younger Adults are Getting Cancer

Systemic Challenges in US Health Care Push Cancer Patients to Fly to China

VERAXA Biotech AG (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

Earth Science Tech Inc.’s (ETST) Shareholders Approve Key Proposals in Annual Meeting

Rising Rates of the Uninsured Could Affect Every American

Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search